OncoImmune
OncoImmune is a clinical-stage biopharmaceutical company founded in 2000 and based in Rockville, Maryland, developing therapeutic solutions for cancer treatment, with founders Yang Liu and Pan Zheng leading science and medical functions.
- Company typePublic
- Founded1891
- HeadquartersRockville, United States
- Headcount5,001–10,000
- GTM typeB2B
- OfferingHardware or Manufacturing
What OncoImmune does
OncoImmune is a clinical-stage biopharmaceutical company founded in 2000 and headquartered in Rockville, Maryland, focused on developing therapeutic solutions for cancer. The company was co-founded by Yang Liu, who serves as President and Chief Scientific Officer, and Pan Zheng, who serves as Senior Vice President and Chief Medical Officer, with Weng Tao heading regulatory affairs. Over its operating history, OncoImmune has raised approximately $74 million across three disclosed funding rounds (2017 Series 2 of $15M led by 3E Bioventures; March 2020 round of $3M; and a September 2020 Series 2 of $56M led by Huimei Capital with participation from 3E Bioventures, GBA Fund, GF Xinde Investment Management, and Kaitai Capital), consistent with a clinical-stage biotech scaling research and development. The firm's firmographic website URL resolves to merck.com, indicating a likely acquisition, asset purchase, or commercial integration relationship with Merck & Co., Inc., though specific transaction terms are not detailed in the source data. There are no disclosed commercial products, pricing models, or customer relationships specific to OncoImmune in the available data, and the company's go-to-market motion, revenue mechanics, and downstream customer segments are not characterized. As a result, OncoImmune should be understood as a small, capital-efficient clinical-stage oncology biotech whose near-term value is embedded in pipeline assets and development expertise rather than commercial revenue generation.
OncoImmune firmographics
Firmographics- Name
- OncoImmune
- Legal name
- Merck & Co., Inc., Rahway, New Jersey, USA
- Website
- https://merck.com
- Company type
- Public
- Founded year
- 1891
- Operating status
- Operating
- Headcount range
- 5,001–10,000 employees
- Short description
- OncoImmune is a clinical-stage biopharmaceutical company founded in 2000 and based in Rockville, Maryland, developing therapeutic solutions for cancer treatment, with founders Yang Liu and Pan Zheng leading science and medical functions.
- Ownership category
- akta.pro rank
OncoImmune industry classification
Industry- Product category
- Clinical-stage Immuno-oncology Biopharmaceuticals
- NAICS
- Pharmaceutical and Medicine Manufacturing (3254), Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Oncology & Hematology Pharmaceuticals (HLAIAAAC)
Keywords
Where OncoImmune is headquartered
LocationHeadquarters
- HQ city
- Rockville
- HQ country
- United States
- HQ region
- North America
Offices9 records
Markets served
OncoImmune business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations
Revenue model
- Prescription Pharmaceuticals: Revenue from proprietary prescription drugs across multiple therapeutic areas including oncology, immunology, infectious diseases, and cardiometabolic conditions. Products include KEYTRUDA, JANUVIA, BRIDION, and others.
- Vaccines: Revenue from vaccine products including GARDASIL 9 (HPV vaccine), VAXNEUVANCE, CAPVAXIVE, ERVEBO (Ebola vaccine), and pediatric vaccines.
- Animal Health: Global animal health business unit offering pharmaceuticals and vaccines for companion and livestock animals under brands like BRAVECTO, Nobivac, and BOVILIS.
Go-to-market motion2 records
Distribution channels6 records
Marketing channels8 records
OncoImmune product offering
Product offeringCore offering
OncoImmune is a clinical-stage biopharmaceutical company developing immuno-oncology therapeutics for cancer treatment, focused on novel immunomodulatory approaches including CD24-based therapeutics for cancer and inflammatory diseases. The company advanced candidates through preclinical and clinical development toward eventual commercialization, partnership, or licensing with larger pharmaceutical companies.
Product overview
Merck operates as a diversified pharmaceutical company with multiple therapeutic areas including oncology, vaccines, infectious diseases, cardiometabolic disorders, and animal health. The company offers a broad portfolio of prescription medicines, vaccines, and animal health products. Key products include KEYTRUDA (pembrolizumab) for cancer treatment, GARDASIL 9 for HPV prevention, and various vaccines including pneumococcal and Ebola vaccines. The cardiometabolic portfolio includes diabetes treatments like JANUVIA and newer SGLT2 inhibitors like STEGLATRO. Infectious disease treatments cover HIV (ISENTRESS, DELSTRIGO), hepatitis C (ZEPATIER), and COVID-19 (LAGEVRIO). Animal health products include BRAVECTO for flea/tick prevention in pets and various livestock vaccines.
Differentiator
Problem solved
Functional benefit
Brands
- Merck for Mothers: Global initiative to help create a world where no woman has to die while giving life, focused on advancing high-quality maternity care, harnessing innovations for maternal health, and catalyzing solutions that respond to local needs.
- Merck Animal Health
- MSD Animal Health
- Merck Manuals
- MSD Manuals
- MerckHelps
Quantifiable outcome
- 167M+ people impacted with access to strengthened health systems through Merck for Mothers
- +2 more outcomes
Companies that use OncoImmune
Customer profileSegments2 records
Ideal customer profiles1 record
OncoImmune technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
OncoImmune partnerships and signals
Strategic signalPartnerships
19 partnerships are on record, tiered core and secondary.
- City Cancer ChallengecoreMerck and City Cancer Challenge expanded global partnership to strengthen women's cancer care, aiming to reach more than 300,000 women living with cancer around the world by 2030.
- PATHcoreCollaboration with global nonprofit PATH to identify game-changing technologies addressing maternal mortality through postpartum hemorrhage (PPH) and preeclampsia solutions, including heat-stable carbetocin and magnesium sulfate administration optimization.
- Ferring PharmaceuticalscorePartnership with Ferring and WHO to advance heat-stable carbetocin for preventing postpartum hemorrhage. Completed largest clinical trial in PPH with nearly 30,000 women from 10 countries.
- World Health Organization (WHO)coreCollaboration on heat-stable carbetocin development and global health initiatives including Saving Mothers, Giving Life partnership addressing maternal mortality during labor, delivery, and first 24 hours postpartum.
- Jhpiego IndiasecondaryLaunched Manyata initiative to improve quality of maternity care in private facilities in India by training doctors, nursing, and administrative staff on clinical and facility protocols.
- Pledge Guarantee for Health (PGH)secondaryInnovative financing partnership leveraging private sector funding to speed delivery and access to life-saving health supplies including contraceptives, bed nets, and medicines.
- EisaicoreCollaboration with Eisai to leverage each company's unique strengths to help advance cancer research, including combination therapy development.
- American Cancer SocietysecondaryPartnership for collaboration on early detection of lung cancer, combining resources for cancer research and patient advocacy.
- Centers for Disease Control and Prevention (CDC)coreFunding support for CDC's Hear Her maternal health communication campaign bringing attention to maternal mortality and providing support to pregnant and postpartum women.
- UNICEFsecondarySupport through global grants for innovative maternal health projects in Bulgaria and Serbia designed to meet unique local needs.
- USAIDsecondaryPartner in MOMs Initiative to stimulate innovations for maternal health improvements in developing regions.
- Lazarex Cancer FoundationsecondaryPartnership to bridge diversity gaps in cancer clinical trials, working to increase participation among historically underrepresented communities.
- AccenturesecondaryJoint program capAbility in Action launched with Accenture and workforce solutions company Rangam to attract, recruit and retain neurodivergent talent.
- OneTensecondaryCoalition of leading companies driving Skills-First movement to unlock career opportunities for talent without four-year degrees.
- Year UpsecondaryNonprofit offering economically disadvantaged youth six months of training followed by six-month corporate internship.
- Hiring Our HeroessecondaryOrganization connecting military community to civilian employers and helping upskill service members for post-service careers.
- Valuable 500secondaryGlobal partnership of 500 companies committed to accelerating disability inclusion through best practices including digitally accessible technology and mental health awareness.
- N.C. A&T (North Carolina A&T State University)secondaryPartnership to launch collaborative biotechnology learning center supporting future talent development in biotech.
- Merck Animal HealthcoreMerck's global animal health business unit focusing on discovering and developing preventative solutions for existing and emerging diseases in animals and people under One Health approach.
Scale indicators9 records
Recent moves5 records
Expansion highlights4 records
OncoImmune competitors and assessment
Company assessmentMarket position
Competitive moat3 records
Key risks5 records
Key highlights5 records
Customer concentration
OncoImmune social profiles
Digital presenceOncoImmune financial estimates
Financial estimateRevenue estimate
Valuation estimate
OncoImmune leadership team
Management profileNumber of profiles
Profiles3 records
OncoImmune subsidiaries and ownership
Company hierarchySubsidiaries2 records
OncoImmune funding detail
Funding detailFunding overview
Funding rounds3 records
Investors5 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
OncoImmune M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about OncoImmune
What does OncoImmune do?
OncoImmune is a clinical-stage biopharmaceutical company developing immuno-oncology therapeutics for cancer treatment, focused on novel immunomodulatory approaches including CD24-based therapeutics for cancer and inflammatory diseases. The company advanced candidates through preclinical and clinical development toward eventual commercialization, partnership, or licensing with larger pharmaceutical companies.
Is OncoImmune a public or private company?
OncoImmune is a public company. It is classified as venture growth investor backed and is currently operating.
When was OncoImmune founded?
OncoImmune was founded in 1891. It employs 5,001 to 10,000 people.
Where is OncoImmune based?
OncoImmune is headquartered in Rockville, United States, in the North America region.
How does OncoImmune make money?
Three revenue lines are on record. Prescription Pharmaceuticals are the primary driver. The others are vaccines and animal Health.
Does OncoImmune have an API?
No public API is recorded for OncoImmune.
What industry is OncoImmune in?
OncoImmune's product category is Clinical-stage Immuno-oncology Biopharmaceuticals. Its primary akta.pro industry code is HLAIAAAC, Oncology & Hematology Pharmaceuticals. Its NAICS code is 3254 and its SIC code is 2834.